William M. Sikov, MD

Articles by William M. Sikov, MD

Dr Sikov on the Use of CDK4/6 Inhibitors in the First-line Treatment of ER+/HER2- Breast Cancer

April 7th 2023

William M. Sikov, MD, discusses the negative outcome seen with palbociclib in the phase 3 PALOMA-2 trial, and compares this to data on other CDK4/6 inhibitors in the first-line treatment of estrogen receptor–positive, HER2-negative breast cancers.

Dr Sikov on the Benefit of CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer

ByWilliam M. Sikov, MD

March 29th 2023

William M. Sikov, MD, discusses the benefit of CDK4/6 inhibitors in the treatment of hormone receptor–positive/HER2-negative breast cancers.

William M. Sikov, MD

Articles by William M. Sikov, MD

Dr Sikov on the Use of CDK4/6 Inhibitors in the First-line Treatment of ER+/HER2- Breast Cancer

Dr Sikov on the Benefit of CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC